May 26, 2012

New oral anticoagulants in atrial fibrillation: top review articles

UPDATED DEC 02, 2013

 TOP 10 REVIEWS  on novel oral anticoagulants in atrial fibrillation, in reverse chronological order of appearance in PubMed.
Click on the title of the study to link to the abstract in PubMed.

 VIP  Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation.
Savelieva I, Camm AJ.
Clin Cardiol. 2013 Nov 19. [Epub ahead of print]
“…a range of practical questions relating to the novel oral anticoagulants has emerged, including topics such as patient selection, treatment of patients with renal impairment, risk of myocardial infarction, drug interactions, switching between anticoagulants, and management of bleeding, in addition to use of these agents in patients requiring antiplatelet drug treatment or undergoing cardioversion or percutaneous interventions (eg, ablation). In this review, practical aspects of the use of novel oral anticoagulants in patients with atrial fibrillation are discussed, with reference to available data and guidance from prescribing information.”

 VIP  Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM, Berge E.
Cochrane Database Syst Rev. 2013 Aug 8;8:CD008980. [Epub ahead of print]
“CONCLUSIONS: Factor Xa inhibitors significantly reduced the number of strokes and systemic embolic events compared with warfarin in patients with AF. Factor Xa inhibitors also seem to reduce the number of major bleedings and ICHs compared with warfarin, though the evidence for a reduction of major bleedings is somewhat less robust. There is currently no conclusive evidence to determine which factor Xa inhibitor is more effective and safer for long-term anticoagulant treatment of patients with AF as head-to-head studies of the different factor Xa inhibitors have not yet been performed.”
Huber K, Connolly SJ, Kher A, et al.
Int J Clin Pract. 2013 Apr 5. [Epub ahead of print]

 VIP  Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.
Alberts MJ, Eikelboom JW, Hankey GJ.
Lancet Neurol. 2012 Dec;11(12):1066-81.
“The direct thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious and safe as warfarin. Their advantages are predictable anticoagulant effects, low propensity for drug interactions, and lower rates of intracranial haemorrhage than with warfarin. A disadvantage is the continuing need to develop and validate rapidly effective antidotes for major bleeding and standardised tests that accurately measure plasma concentrations and anticoagulant effects, together with the disadvantage of possible higher rates of gastrointestinal haemorrhage and greater expense than with warfarin.”

 VIP  Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Kosar L, Jin M, Kamrul R, Schuster B.
Can Fam Physician. 2012 Aug;58(8):850-8. No abstract available.

Ru San T, Chan MY, Wee Siong T, et al.
Thrombosis. 2012;2012:108983. Epub 2012 Sep 10.

 VIP  New oral anticoagulants for atrial fibrillation.
Spinler SA, Shafir V.
Circulation. 2012 Jul 3;126(1):133-7. No abstract available.

Katsnelson M, Sacco RL, Moscucci M.
Circulation. 2012 Mar 27;125(12):1577-83.

Liew A, Eikelboom JW, O'Donnell M.
Curr Opin Cardiol. 2012 May 8. [Epub ahead of print]

Bassand JP.
Europace. 2012 Mar;14(3):312-24.

 VIP  means very important / interesting paper